VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU
Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery
The talk show will be held monthly via Medanta's YouTube, Facebook and LinkedIn channe
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion diagnostics business.
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
1,000 Ph.D. students will be enrolled in the next five years to drive innovation in the critical healthcare sector
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
Subscribe To Our Newsletter & Stay Updated
